Home › Funds › PSP Research LLC › SYRE
PSP Research LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
PSP Research LLC reported holding 4,000 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$355K, representing 0.19% of its reported portfolio and ranking #42 among its reported holdings. PSP Research LLC has disclosed SYRE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
How PSP Research LLC's SYRE position evolved
PSP Research LLC first disclosed a stake in SYRE in Q4 2025 at 15,840 shares (US$519K). Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,000 shares valued at US$355K. Notable position changes include a 67% trim in Q1 2026 (shares rose 76% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 15.84K | $518.92K | New |
| Q1 2026 | 5.16K | $260.22K | Reduce |
| Q2 2026 | 4.00K | $355.12K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 71 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M sh · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.46M sh · $129.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.56M · Q2 2026
- Siren, L.L.C. 968.60K sh · $85.99M · Q2 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026